Pressemeddelelse

Senzime launches TetraSensitive, the market's first sensor for neuromuscular monitoring of patients with sensitive skin

Uppsala, Sweden, October 9, 2023: Senzime, a leader in algorithm-based patient monitoring solutions, today launched TetraSensitive, the market’s first disposable electromyography (EMG)-powered sensor intended for neuromuscular monitoring (NMT) of patients with sensitive skin. TetraSensitive, with a unique, patented design, targets a rapidly growing number of patients with delicate and fragile skin undergoing surgical procedures.

More than half of all surgical procedures are performed on patients over 65 years of age. Due to ageing, the skin becomes more fragile because of a gradual loss of subcutaneous fat, causing skin to become more vulnerable to the damage that may be caused by conventional adhesives used in monitoring patches.

Senzime’s new TetraSensitive is the first EMG sensor designed specifically for neuromuscular monitoring of patients with sensitive and fragile skin. Its novel design combines advanced technology using an ultrasoft stretchable material and a flexible silver print to create a natural contact with the skin and eliminate discomfort. TetraSensitive is developed to provide superior adhesion without sharp edges, and the smart sizing design makes it ideal for different patient sizes. The TetraSensitive is protected by valid EU and US patent laws.

“Senzime continues to launch innovations to advance patient safety and help eliminate postoperative complications. We now offer the only complete portfolio of EMG sensors meeting pediatric, adult and skin-sensitive patient needs to the US and EU market,” commented Philip Siberg, CEO of Senzime.

The new disposable TetraSensitive EMG sensor is used with the portable TetraGraph quantitative neuromuscular monitor. The new product will be showcased at Anesthesiology 2023, the American Society of Anesthesiologists annual meeting, in San Francisco, October 13-17, and will be available for customer deliveries in US and European markets from early November 2023.

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.